SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive analyst upgrade that highlights the company's progress in regulatory pathways and validates the therapeutic potential of its lead candidate, Sonelokimab. Investors are actively discussing the stock's significant long-term growth prospects, the potential for a strategic buyout, and the upcoming clinical data readouts that are expected to solidify the drug's position as a best-in-class treatment.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is facing intense volatility as shareholders grapple with the end of a major lock-up period and skepticism following a disappointing earnings report that revealed a lack of near-term tenant revenue. The community is sharply divided, with some investors aggressively calling for leadership changes and reporting the firm to the SEC, while others view the current price drop as a strategic buying opportunity in anticipation of future data center power demand.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community leans into its roots as a foundational internet meme, bolstered by the restoration of its original RageBuilder and Ragemaker tools. Enthusiasts are actively rallying around the project as a long-term culture play, emphasizing organic growth and community-driven content production as they target long-term valuation milestones.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following a series of significant Department of Defense and defense-contractor awards, which have sparked intense community debate over the company's long-term production scalability and balance sheet health. While bulls point to these mission-critical manufacturing contracts as validation of the company's technology, short-sellers and skeptical investors remain focused on ongoing cash burn concerns and the potential for future equity dilution.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is seeing heightened trading activity as the company's recent operational updates and offtake agreements drive significant investor interest, leading to strong buying momentum in the stock. The community is actively debating the stock's potential for a breakout, with many discussing the impact of lithium supply-demand dynamics and monitoring insider buying as a key indicator of confidence in future growth.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following the TETON-1 study's success in meeting its primary efficacy endpoint for treating idiopathic pulmonary fibrosis, driving investor optimism regarding the company's pipeline expansion. The community is actively discussing the drug's potential market impact, the competitive landscape involving inhaled treprostinil treatments, and broader implications for the company's valuation as it maintains its strong commercial presence.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors gear up for the upcoming fiscal year-end and 10-K filing, with the community highly focused on QNX revenue growth, backlog expansion, and the impact of the new Alloy Kore platform. Shareholders are actively debating management's guidance and the potential for a long-awaited breakout as they look for concrete signs of sustainable double-digit growth.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing intense scrutiny following the release of elegrobart REVEAL-1 phase 3 data, which triggered a significant pre-market stock decline despite meeting primary endpoints. Investors are actively debating the drug's competitive positioning against current standard-of-care treatments, with community sentiment divided between those viewing the pullback as a buying opportunity and skeptics questioning its long-term viability without head-to-head trial data.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air is trending as investors digest the airline's latest quarterly results and guidance, with the market focused on its aggressive growth strategy and integration of Hawaiian Airlines. Community sentiment remains largely bullish, highlighting strong demand, operational efficiency, and a significant share buyback plan that continues to drive positive momentum.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific (BSX) is trending following positive data from the Champion-AF clinical trial, which confirmed the safety and efficacy of the Watchman FLX device compared to standard anticoagulants. Community discourse remains highly active, balancing excitement over the company's clinical innovation with skepticism driven by ongoing litigation, recent analyst price target adjustments, and the broader macro-driven rotation within the medtech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen

Wall Street Zen cut shares of Agenus from a "buy" rating to a "hold" rating in a research note on Sunday...

Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by Brokerages

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the company, MarketBeat Ratings reports. One research...

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Companys patient access programs...

Agenus (NASDAQ:AGEN) Rating Increased to Buy at Wall Street Zen

Wall Street Zen raised shares of Agenus from a "hold" rating to a "buy" rating in a research note on Saturday...

Research Analysts Issue Forecasts for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN - Free Report) - Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Agenus in a research note issued on Monday, March 16th. HC Wainwright...

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab...

Agenus (NASDAQ:AGEN) Issues Quarterly Earnings Results

Agenus (NASDAQ:AGEN - Get Free Report) issued its earnings results on Monday. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of...

Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates

Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL...

CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates

CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Current Price	$3.39
Prev Close	$3.44
Open	$3.44
Dividend Yield	0.00%
50-Day Moving Average	$3.22
Beta	1.93
Avg. Volume	393,480.54
PE Ratio	-8.73

52-Week High	$7.34
52-Week Low	$1.38
Market Capitalization	$130.17M
EPS (Annual)	-$0.0034
Price to Book	-0.44
Revenue Per Employee	$1.41M

AGEN
Agenus Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGEN News

AGENAgenus Inc